Skip to main content

COVID-19 and the APAC CRO Landscape | Avance Clinical featured in Biospectrum Asia

By January 5, 2021July 13th, 2021Company News

“Australia has been recognized globally for its handling of the COVID-19 pandemic with strict quarantine systems and advanced contact tracing, resulting in low numbers of cases and deaths. Therefore we have seen a dramatic increase in the number of USA sponsors moving their trials to Australia.” Read the full article here

The global disruption presented a number of operational challenges including:

  • A need to rapidly pivot to full adoption of eClinical technologies because traditional working practices and methods were no longer practical.
  • Initially, patient/volunteer participation in clinical trials decreased at some sites because participants were not wanting to attend clinics or hospitals for fear of the virus.
  • Some sites in Australia were temporarily closed while they introduced new work practices to protect staff and patients/volunteers.
  • COVID-19 studies targeting countries with significant patient populations, rapidly dominated the global sector, resulting in decreased attention, site resources and funding for non-COVID related therapies.
  • Employee adaptions to new working environments i.e. working from a home office.
  • Conduct of business development activities needed to change as the ability to create new business connections and partnerships via conferences and face-to-face meetings became no longer possible.

Leave a Reply


DOWNLOAD OUR LATEST WHITEPAPER

Why 65% of US Biotechs Struggle to Identify Suitable CRO Partner

By filling in this form you consent to Avance Clinical contacting you. Read our Privacy Policy
This field is for validation purposes and should be left unchanged.

This will close in 0 seconds